OBI Pharma
4174.TWOTaipei, Taiwan· Est.
Taiwan‑based ADC specialist OBI Pharma advances glycan‑engineered antibody‑drug conjugates for oncology.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
Taiwan‑based ADC specialist OBI Pharma advances glycan‑engineered antibody‑drug conjugates for oncology.
Oncology
Technology Platform
OBI’s GlycOBI® platform uses precise glycan modifications and novel linker chemistries to create plug‑and‑play ADCs with controlled DAR and enhanced stability, applicable to any antibody scaffold.
Opportunities
Advancing OBI‑902 through pivotal trials and licensing the GlycOBI® platform to larger pharma partners could drive significant revenue and market penetration.
Risk Factors
Clinical trial failures, regulatory hurdles, and intense competition from established ADC developers pose major risks to OBI’s growth trajectory.
Competitive Landscape
OBI competes with major ADC players such as Seagen, Roche, and AstraZeneca, differentiating itself through glycan‑engineered conjugation that promises higher product uniformity and manufacturing efficiency.